The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

The Food and Drug Administration allows for licensed compounding pharmacies to make copies of certain drugs in short supply, and that has included semaglutide and tirzepatide, the main ingredients in ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Semaglutide and a similar compound, tirzepatide, had been on the FDA’s shortages list since 2022, and the popularity of the ...

The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...

suggest that perhaps with the right compound and the right dosing, a GLP-1 agonist may work. More clinical trials are ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths ...